Diagnosis, management and follow up of peripheral T cell lymphomas: A Consensus Practice Statement from the Australasian Lymphoma Alliance.

2021-10-20

Hapgood, G

Latimer, M

Lee, Sze Ting

Kuss, B

Lade, S

Tobin, J W D

Purtill, D

Campbell, B A

Prince, H M

Hawkes, Eliza A

Shortt, J

Radeski, D

AITL

ALCL

PTCL

Peripheral T-cell Lymphoma

chemotherapy

Journal Article

0000-0002-7980-8496

0000-0001-8641-456X

0000-0002-0376-2559

10.1111/imj.15595

Peripheral T-cell lymphomas (PTCLs) represent a heterogeneous disease group accounting for 10% of non-Hodgkin lymphomas. PTCL patients have typically poorer outcomes compared to aggressive B-cell lymphomas. However, such outcomes are heavily dependent upon subtype. Although anthracycline-based regimens such as cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) remain the standard first-line treatment for most aggressive PTCLs, there are important variations including incorporation of novel agents, use of radiotherapy and judicious consideration of stem cell transplantation. Relapsed or refractory disease represents a significant area of unmet need where chemotherapy intensification has limited efficacy and novel agents such as brentuximab vedotin and pralatrexate provide additional opportunities for attainment of remission and potential stem cell transplant. In the future, pre-therapy prognostic biomarkers including genomic characterisation, may aid in risk stratification and help guide initial patient management to improve survival. There is an urgent need to better understand the pathogenesis of PTCLs to facilitate novel drug combinatorial approaches to improve survival. This position statement represents an evidence-based synthesis of the literature for application in Australian and New Zealand practice. This article is protected by copyright. All rights reserved.

link

Internal Medicine Journal 2021; online first: 20 October

Internal Medicine Journal